Essential hypertension
Conditions
Interventions
Control group:Valsartan Capsules
Test group:Kugan granules
Sponsors
Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 18 and 85, any gender. (2) Diagnosed with stage 1 hypertension according to Western medicine standards. (3) Display symptoms of excessive liver fire or phlegm-dampness in Traditional Chinese Medicine. (4) Have no history of previous antihypertensive medication use, or have discontinued use for over 2 weeks and meet the above diagnostic criteria. (5) Understand the research content, willingly participate in this study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Secondary hypertension or hypertensive emergency. (2) Pregnant and lactating women. (3) Combined with severe target organ damage, including cerebral hemorrhage, cerebral infarction, myocardial infarction, etc. (4) Patients with severe liver and kidney function impairment or combined with heart, lung and other organ failure. (5) Those who have clear contraindications and allergies to the test drugs (components of traditional Chinese medicine granules, ARB). (6) Those with severe hearing, language, communication and cognitive dysfunction and unable to complete the scale; (7) Currently participating in other drug clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Office Blood Pressure;Ambulatory blood pressure;Main symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Four items of blood lipid tests;Fasting plasma glucose;Glycated serum proteins;Fasting insulin;Uric acid; | — |
Countries
China
Contacts
Public ContactShi Wang
Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)
Outcome results
None listed